A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.
Andrew Hahn, MD
Advertisement
Andrew Hahn, MD, is a medical oncologist at MD Anderson Cancer Center.
Articles by Andrew Hahn, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
3
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
4
Lurbinectedin and Tarlatamab in ES-SCLC
5
